Skip to main content

Table 1 Patient demographics and baseline characteristics

From: Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East

 

Fingolimod cohort

N = 172

Other DMTs cohort

N = 75

Total

N = 247

Age (years)

 Mean

36.7 ± 11.2

36.2 ± 12.2

36.5 ± 11.5

 Median (min–max)

35.0 (18.0–64.0)

34.0 (18.0–68.0)

34.0 (18.0–68.0)

Women, n (%)

112 (65.1)

47 (62.7)

159 (64.4)

BMI (kg/m2), n (%)

 Overweight (25 ≤ BMI < 30)

47 (27.3)

14 (18.7)

61 (24.7)

 Obese (BMI ≥30)

18 (10.5)

12 (16.0)

30 (12.1)

Race, n (%)

 Caucasian

153 (89.0)

68 (90.7)

221 (89.5)

 Asian

4 (2.3)

1 (1.3)

5 (2.0)

 Other

15 (8.7)

6 (8.0)

21 (8.5)

MS disease history

 Duration since MS diagnosis (years)

  Mean

7.2 ± 6.1

4.8 ± 6.8

6.5 ± 6.4

  Median (min–max)

5.3 (0.0–32.0)

1.2 (0.0–23.9)

4.2 (0.0–32.0)

 Duration since the first MS symptoms (years)

  Mean

9.4 ± 7.6

7.5 ± 9.1

8.9 ± 8.1

  Median (min–max)

7.3 (0.1–34.7)

3.2 (0.0–44.1)

6.6 (0.0–44.1)

 Duration since the most recent MS relapse (months)

  Mean

10.4 ± 14.8

6.1 ± 8.6

9.0 ± 13.2

  Median (min–max)

5.0 (0.0–87.0)

3.0 (0.0–50.0)

4.0 (0.0–87.0)

 Number of MS relapses in the 12 months before baseline

  Mean

1.1 ± 0.9

1.2 ± 0.8

1.1 ± 0.9

  Median (min–max)

1.0 (0.0–5.0)

1.0 (0.0–3.0)

1.0 (0.0–5.0)

 Number of MS relapses 12–24 months before baseline

  Mean

0.9 ± 1.1

0.5 ± 0.8

0.8 ± 1.0

  Median (min–max)

1.0 (0.0–5.0)

0.0 (0.0–3.0)

0.0 (0.0–5.0)

 History of MS patients before study, n (%)

  Treatment-naïve patients a

24 (14.0)

46 (61.3)

-

  Patients on any approved MS DMT

148 (86.0)

29 (38.7)

-

Type of DMTs prescribed before study entry, n (%)

 Fingolimod

8 (5.4)

4 (13.8)

-

 Any interferon β

103 (69.6)

15 (51.7)

-

 Glatiramer acetate

17 (11.5)

8 (27.6)

-

 Natalizumab

16 (10.8)

2 (6.9)

-

 Other

4 (2.7)

0 (0.0)

-

  1. Data are presented as mean ± SD, unless stated otherwise; percentages were calculated based on the total number of patients in each treatment cohort (n)
  2. BMI body mass index, DMT disease-modifying treatment, MS multiple sclerosis, min minimum, max maximum, SD standard deviation
  3. aTreatment-naïve patients are patients who had never received any MS DMT before study entry (±4 weeks)
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us